GEN Exclusives

More »

GEN News Highlights

More »
Sep 5, 2007

Bayer Schering Pharma Contracts Dyax to Discover Therapeutic mAbs

  • Dyax inked an agreement with Bayer Schering Pharma for the discovery of therapeutic antibodies. Bayer Schering Pharma will provide two targets, and Dyax will identify related antibodies.

    Dyax will receive milestone payments and royalties. The deal also provides Bayer Schering Pharma with sublicenses to relevant third-party antibody phage display patents that may be used with Dyax' technology.

    These research activities may be expanded to allow Dyax to work on additional targets and/or allow Bayer Schering Pharma to exercise an option for an antibody library license.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

Be sure to take the GEN Poll

Tackling the Global Problem of Fake Medicines

Policy proposals to address the growing global problem of fake medicines include a global agreement, similar to the Framework Convention on Tobacco Control, and stricter national laws to prosecute those who knowingly sell counterfeit medicines. Do you think these steps will be successful?

More »